SUBSCRIBE
SUBSCRIBE

Alkermes

NEWS
Policy
FDA Eyes Safety Of Popular Anemia Drugs
October 19, 2005
 · 
1 min read
Business
ConjuChem
October 19, 2005
 · 
8 min read
Biotech Moves Ahead Of Major Indexes
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
May 12, 2026
 · 
18 min read
Press Releases
Alkermes plc Reports First Quarter 2026 Financial Results
May 5, 2026
 · 
1 min read
Press Releases
Alkermes to Report First Quarter Financial Results on May 5, 2026
April 22, 2026
 · 
1 min read
Press Releases
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
April 17, 2026
 · 
10 min read
Press Releases
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
April 14, 2026
 · 
16 min read
Press Releases
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
April 2, 2026
 · 
6 min read
Press Releases
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
March 12, 2026
 · 
3 min read
Press Releases
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
March 11, 2026
 · 
1 min read
Press Releases
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
February 25, 2026
 · 
1 min read
Press Releases
Alkermes plc Announces CEO Succession Plan
February 25, 2026
 · 
9 min read
Load More